CapsoVision (CV) EBT Margin (2024 - 2025)
CapsoVision recorded quarterly EBT Margin of 188.11% in Q4 2025, up 15.98% quarter-over-quarter from 223.88% in Q3 2025, and down 5404.0% year-over-year from 3.55% in Q4 2024.
CapsoVision's EBT Margin history runs 2 years deep, the most recent figure standing at 188.11% for Q4 2025.
- In Q4 2025, EBT Margin fell 5404.0% year-over-year to 188.11%; the TTM figure through Dec 2025 stood at 172.57% (changed N/A YoY), while the FY2025 annual figure was 186.59%, down 1743.0% from the prior year.
- EBT Margin came in at 188.11% for Q4 2025 at CapsoVision, up from 223.88% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 134.07% in Q4 2024 to a low of 223.88% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 15.57% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 27.84% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 4.87% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 22.61% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.84% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.17% |
| 10 | CapsoVision | 167.59 Mn | 157.48 Mn | 1.95 Mn | -188.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -188.11% |
| Sep 30, 2025 | -223.88% |
| Jun 30, 2025 | -139.52% |
| Dec 31, 2024 | -134.07% |
| Sep 30, 2024 | -195.35% |
| Jun 30, 2024 | -185.23% |